Artivion (NYSE:AORT) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Artivion (NYSE:AORT - Get Free Report) posted its quarterly earnings results on Monday. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.06), Zacks reports. The business had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Artivion updated its FY 2025 guidance to EPS.

Artivion Trading Up 2.0 %

Shares of AORT stock traded up $0.56 during trading hours on Thursday, hitting $28.94. 221,213 shares of the company were exchanged, compared to its average volume of 314,324. Artivion has a 1 year low of $21.97 and a 1 year high of $32.33. The firm has a fifty day moving average of $24.02 and a 200 day moving average of $27.19. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a market cap of $1.24 billion, a PE ratio of -1,447.00 and a beta of 1.54.

Analysts Set New Price Targets

Several research firms have weighed in on AORT. Needham & Company LLC restated a "buy" rating and issued a $32.00 price objective on shares of Artivion in a research report on Tuesday. JMP Securities reiterated a "market outperform" rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday. Citizens Jmp raised Artivion to a "strong-buy" rating in a research note on Tuesday. Finally, Stifel Nicolaus lowered their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $31.40.

Insider Buying and Selling at Artivion

In related news, insider John E. Davis sold 6,457 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $27.31, for a total value of $176,340.67. Following the sale, the insider now owns 160,631 shares in the company, valued at approximately $4,386,832.61. This represents a 3.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 5,335 shares of Artivion stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at approximately $4,091,010.69. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock worth $2,356,223 in the last ninety days. 7.60% of the stock is owned by insiders.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.